Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial.

Polite BN, Desai AA, Manchen B, Stadler WM. Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial. Clin Genitourin Cancer. 2006 Mar; 4(4):275-80.

View in: PubMed

collapse authors with profiles